

Baseline Characteristics of Patients Enrolled in PolarisDMD, a Phase 3 Trial of Edasalonexent for Duchenne Muscular Dystrophy

Richard S. Finkel MD¹, Craig McDonald MD², Lee Sweeney PhD², Kathryn Wagner MD PhD⁴, Erin Neil DO⁵, Maria Mancini MHP⁶, James MacDougall PhD⁶, Joanne M. Donovan MD PhD⁶ for the PolarisDMD Investigators

¹Nemours Children's Health System, Orlando, FL, ²UC Davis, Sacramento, CA, ³University of Florida, Gainesville, FL, ⁴Kennedy Krieger Institute, Baltimore, MD, ⁵University of Michigan, Ann Arbor, MI, ⁶Catabasis Pharmaceuticals, Boston, MA







Study Design

POLARIS	GALAXYDMD
12-month, randomized, double-blind placebo-controlled trial (n=131)	Open-label extension
Edasalonexent 100 mg/kg	> Edasalonexent
Placebo	>
Primary End	point
Eligibility:	
 All mutations Age 4 to 7 (up to 8th birthday); off steroids for ≥6 i Able to swallow placebo capsules at the Screening 	
Endpoints measured at Screening and Baseline, w	vith Primary Endpoint at 52 Weeks:
 Primary: Change in North Star Ambulatory Assess Key secondary: Velocity of age-appropriate timed Additional assessments include growth, cardiac ar 	function tests
Top-line results expected in Q4 2020	

Results

Reproducibility of Additional Functional Measures Between Screening and Baseline		
The NSAA and timed function tests were highly reproc PolarisDMD study population	lucible in the Phase 3	
NSAA was more reproducible than the timed function tests in this population		
	Pearson Correlation Coefficient	
North Star Ambulatory Assessment (NSAA) score	0.84	
10-Meter Walk/Run speed (1/s)	0.82	
4-Stair Climb speed (1/s)	0.81	

Acknowledgements







Catabasis